[Federal Register: December 9, 2003 (Volume 68, Number 236)]
[Page 68627]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]



Food and Drug Administration

Oncologic Drugs Advisory Committee; Amendment of Notice

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.


SUMMARY: The Food and Drug Administration (FDA) is announcing an 
amendment to the notice of meeting of the Oncologic Drugs Advisory 
Committee. This meeting was announced in the Federal Register of 
November 18, 2003 (68 FR 65076-65077). The amendment is being made to 
reflect a change in the Location portion of the document. There are no 
other changes.

FOR FURTHER INFORMATION CONTACT: Johanna Clifford, Center for Drug 
Evaluation and Research (HFD-21), Food and Drug Administration, 5600 
Fishers Lane, Rockville, MD 20857, or by express delivery to: 5630 
Fishers Lane, rm. 1093, Rockville, MD 20852, 301-827-7001, or FDA 
Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in 
the Washington, DC area), code 3014512542. Please call the Information 
Line for up-to-date information on this meeting.

SUPPLEMENTARY INFORMATION: In the Federal Register of November 18, 2003 
(68 FR 65076-65077), FDA announced that a meeting of the Oncologic 
Drugs Advisory Committee would be held on December 16, 2003. On page 
65077, in the first column, the Location portion of the meeting is 
amended to read as follows:
    Location: CDER Advisory Committee conference rm. 1066, 5630 Fishers 
Lane, Rockville, MD.
    This notice is issued under the Federal Advisory Committee Act (5 
U.S.C. app. 2) and 21 CFR part 14, relating to advisory committees.

    Dated: December 3, 2003.
William K. Hubbard,
Associate Commissioner for Policy and Planning.
[FR Doc. 03-30436 Filed 12-8-03; 8:45 am]